Background Oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir (F/TDF) is highly effective in preventing HIV-1 acquisition, but uptake and adherence remain suboptimal. Long-acting injectable cabotegravir (CAB-LA) has shown high efficacy in trials, though real-world effectiveness data remain limited. We evaluated initial PrEP choices, reasons for selection, and associated factors in ImPrEP CAB Brasil, the first study to … Continue reading 1356 – PrEP Choices Among Sexual and Gender Minorities in Brazil: The ImPrEP CAB-LA Study